Insider Buying: GSK (LON:GSK) Insider Purchases £10,150.84 in Stock

GSK plc (LON:GSK) insider Anne Beal purchased 196 shares of the company’s stock in a transaction on Friday, March 20th. The shares were bought at an average price of GBX 5,179 per share, for a total transaction of £10,150.84.

GSK Trading Up 3.5%

GSK stock opened at GBX 2,046 on Thursday. GSK plc has a 12-month low of GBX 1,242.50 and a 12-month high of GBX 2,282. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. The stock has a market capitalization of £82.07 billion, a PE ratio of 14.74, a price-to-earnings-growth ratio of 1.24 and a beta of 0.32. The firm has a 50 day simple moving average of GBX 2,031.72 and a 200-day simple moving average of GBX 1,825.76.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. As a group, equities research analysts expect that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft boosted their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,100 price objective on shares of GSK in a research note on Wednesday, January 7th. Shore Capital Group reissued a “buy” rating on shares of GSK in a research note on Wednesday. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Finally, UBS Group reaffirmed a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a report on Friday, January 23rd. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of GBX 1,917.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.